DeKalb Medical is one of the first four study sites to be activated for a phase 2 clinical trial evaluating CF-301 in patients with Staphylococcus Aureus Bacteremia. Adam Bressler, M.D. of Infectious Disease Specialists of Atlanta (IDSA), is the principal investigator in this trial which is a new concept in medicine that may someday replace antibiotics.
According to Robin Dretler, M.D., also with IDSA, this is a groundbreaking study. “In this study, we will treat staph infections at DeKalb Medical with the current standard of care antibiotics, but half will get an additional dose of a bacteria killing lysin from a recombinant (medically created) bacteriophage.”